Our Pipeline: First-In-Class
Bicara has more than a platform: We have a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors, including a lead program that’s already in the clinic.
- PROGRAMTARGETDISCOVERYIND-ENABLINGPHASE 1PHASE 2PHASE 3Indication
- BCA101EGFR / TGF-βmonotherapycombination with pembrolizumabEGFR / TGF-βcSCCHNSCC, SCAC
- BCA356precision immunocytokineprecision immunocytokineSolid Tumors
- BCA600precision immunecell engagerprecision immunecell engagerSolid Tumors
- BCA500UndisclosedUndisclosedSolid Tumors
We have taken a pragmatic approach to building our pipeline. We seek out a powerful biological rationale and strong potential to address significant unmet needs, which include patients who are refractory to immune checkpoint inhibitors and first-line targeted therapies.
Posters and Publications
Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting, November 2021
American Society of Clinical Oncology, June 2021
Our Lead Program: BCA101
First-in-class EGFR / TGFβ-trap bifunctional antibody
Epidermal growth factor receptor (EGFR), a protein expressed on the surface of several tumor types, is one of the most extensively validated tumor-associated antigens.
Monoclonal antibodies directed at EGFR suppress the proliferation of EGFR-driven tumor cells and restrict tumor growth and metastasis. Inhibiting EGFR alone is inadequate to achieve durable therapeutic responses. Our solution: Simultaneous inhibition of EGFR and TGFβ — a signaling molecule that promotes tumor growth in the presence of EGFR and that plays a key role in suppressing the immune response in the tumor microenvironment.
Our lead program is thus a dual-action bifunctional antibody that both inhibits EGFR and disables TGFβ directly at the site of the tumor. With this approach, we hope to achieve superior anti-tumor efficacy with an improved therapeutic window.
Phase 1/2 Clinical Study
We have completed dose escalation studies evaluating BCA101 as a single-agent and in combination with pembrolizumab, and have initiated the dose expansion arm of our clinical study.
BCA101 will be administered in combination with pembrolizumab as first-line therapy in patients with unresectable, recurrent or metastatic HNSCC and as second-line therapy in patients with advanced SCAC who have received prior chemotherapy. A third cohort of patients with advanced or incurable cSCC who have received previous anti-PD-1 therapy will be treated with BCA101 as a single agent.
For more information, please visit clinicaltrials.gov.
Enrolling trial sites
New York, NY
New York, NY
Los Angeles, CA
San Diego, CA